PDCD1 and metastatic melanoma: In metastatic melanoma, the downregulation of VISTA, PTEN, and HLA is evidently associated with anti-PD-1 mAb resistance, and it has been discovered that pharmacological inhibition of the VISTA signal pathway may be considered to synergistically enhance the efficacy of anti-PD-1 therapy (88).